girentuximab
heidelberg pharmaceuticals,esteve,prometheus
['rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)', 'kidney cancer', 'zircon', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'kcsm,(-skcsm)', 'girentuximab', 'imab ']
 #gu23 zr-89 girentuximab zircon trial of n=332. approx 93% positive predictive value for clear cell kidney cancer in primary masses &lt;7cm. sensitive also in subgroup &lt;4cm. a new molecular biopsy option for #kidneycancer? #radonc #kcsm 
Radiation Oncologist at the Peter MacCallum Cancer Centre @petermaccc, Associate Professor University of Melbourne, Australia 🇦🇺. Views are my own. #radonc